Last reviewed · How we verify

NCT04317261

Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria

Completed NA Last updated 23 March 2020
What this trial tests

NA trial testing Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC) in Hematuria in 181 participants. Completed in 1 March 2020.

Timeline
1 March 2018
Primary endpoint
1 March 2020
1 March 2020

Quick facts

Lead sponsorMansoura University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment181
Start date1 March 2018
Primary completion1 March 2020
Estimated completion1 March 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Hematuria or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our goal is to develop a noninvasive, fast and simple assay to detect BCa on the GeneXpert system and metablomic genes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hematuria

Currently open trials in the same condition.

Other Mansoura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04317261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing